25 Posts Not To Miss From ASCO 2026 Day 4
AEGEAN Trial: Durvalumab Reshapes the Tumor Microenvironment in Resectable NSCLC
International Partnerships Aim to Mitigate Cancer Care Disruptions in Ukraine - AACR
Is RAS No Longer Undruggable? Discussions on RASolute Trial That Earned Standing Ovation at ASCO26
HARMONi-6 Trial at ASCO Plenary 2026: Ivonescimab Plus Chemotherapy Improves Overall Survival in Advanced Squamous Non-Small Cell Lung Cancer
mRCAT-III at ASCO 2026: Node-Sparing RT Plus CAPOX and Tislelizumab in MSS Locally Advanced Rectal Cancer
A Year to Remember at ASCO 26 - GI Cancers Alliance
New Trial Tests Trabectedin With Radiotherapy in Retroperitoneal L-Sarcoma
